---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021493"
form_type: "8-K"
ticker: "ECOR"
cik: "0001560258"
company_name: "electroCore, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:38:00.881483+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# electroCore Q1 revenue $9.6M (+43% YoY); reaffirms ~30% FY2026 growth guidance

## Summary
- Net sales $9.6M, record quarterly revenue, up 43% from $6.7M Q1 2025.
- GAAP net loss $5.3M ($0.59 per share); includes $1.9M leadership transition expenses.
- Adjusted EBITDA net loss improved 24% YoY to $2.3M from $3.1M.
- VA prescription gammaCore revenue grew 26% YoY; Quell Fibromyalgia quarterly sales >$1M.
- Michael Fox appointed COO in April 2026; Truvaga launched in UK in January 2026.

## SEC filing metadata
- accession: 0001493152-26-021493
- form_type: 8-K
- ticker: ECOR
- cik: 0001560258
- company_name: electroCore, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1560258/000149315226021493/0001493152-26-021493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1560258/000149315226021493/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021493
- JSON: https://secwatch.observer/filing/0001493152-26-021493.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021493.txt

## Source-grounded claims
- claim_id: e76616be0b3945745cdde9dd7258ca0256bac946
  claim: electroCore, Inc. reported first quarter ended March 31, 2026 results: revenue $9.6 million, net income $5.3 million. Guidance reaffirmed.
  evidence_excerpt: The information contained in this Item 2.02 and --- EX-99.1 (EX-99.1) --- electroCore Announces First Quarter 2026 Financial Results First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1560258/000149315226021493/0001493152-26-021493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.